The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.
2025 · 3rd Quarter (July 1 - Sep 30)
CSL BEHRING LLC
Filed by HARBINGER STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 21, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- HARBINGER STRATEGIES, LLC
- Client
- CSL BEHRING LLC
- Filing UUID
- 666fa2ed-13ee-4c51-978b-a3dd9f50e4a4
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.